Article
Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.
Cancer chemotherapy and pharmacology - 1 Jun 2020
Matsumoto Natsumi, Kubota Yutaro, Ishida Hiroo, Sekido Masae, Ohkuma Ryotaro, Ishiguro Tomoyuki, Hirasawa Yuya, Ariizumi Hirotsugu, Tsunoda Takuya, Ikusue Toshikazu, Kobayashi Kouji, Hisamatsu Atsushi, Toshima Hirokazu, Shimada Ken, Fujita Ken-Ichi
Abstract excerpt
PURPOSE: Capecitabine is a prodrug that undergoes metabolism in three steps to form an active 5-fluorouracil (5-FU). The first step is primarily catalyzed by liver carboxylesterases (CES) 1. Here, we examined the effects of CES1 variants on pharmacokinetics and toxicity of capecitabine. METHODS: We enrolled postoperative colorectal cancer (CRC) patients administered with adjuvant capecitabine plus oxaliplatin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.